A Single-arm, Open-label, Single-dose Clinical Study to Evaluate the Safety and Tolerability of BBM-P002 for Stereotactic Bilateral Putamen Injection in the Treatment of Idiopathic Parkinson's Disease
Latest Information Update: 07 Oct 2025
At a glance
- Drugs BBM P 002 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Shanghai Xinzhi BioMed
Most Recent Events
- 07 Oct 2025 New trial record